Shares of Amarin Corp. plc (NASDAQ: AMRN) rose as much as 2% on Monday on speculation that the company could be acquired by Pfizer Inc. (NYSE: PFE). Amarin Corporation Plc, a clinical-stage biopharmaceutical company, focuses on developing treatments for cardiovascular diseases. Its lead product candidate includes AMR101, a prescription grade omega-3 fatty acid, which is in second Phase III clinical trial for the treatment of high triglyceride levels in statin-treated patients who have mixed dyslipidemia.
Full Disclosure: None.
